[go: up one dir, main page]

CN114846003A - 用于治疗癌症的氘代化合物 - Google Patents

用于治疗癌症的氘代化合物 Download PDF

Info

Publication number
CN114846003A
CN114846003A CN202080070533.0A CN202080070533A CN114846003A CN 114846003 A CN114846003 A CN 114846003A CN 202080070533 A CN202080070533 A CN 202080070533A CN 114846003 A CN114846003 A CN 114846003A
Authority
CN
China
Prior art keywords
compound
formula
compounds
agents
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070533.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·布兰科
M·查尔斯
T·埃克乌鲁
H·芬奇
H·麦卡伦
R·海尔德
M·斯托克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atios Pharmaceutical Co ltd
Original Assignee
Atios Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2019/052240 external-priority patent/WO2021028643A1/en
Priority claimed from GBGB1917863.1A external-priority patent/GB201917863D0/en
Application filed by Atios Pharmaceutical Co ltd filed Critical Atios Pharmaceutical Co ltd
Publication of CN114846003A publication Critical patent/CN114846003A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080070533.0A 2019-08-09 2020-08-10 用于治疗癌症的氘代化合物 Pending CN114846003A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2019/052240 WO2021028643A1 (en) 2019-08-09 2019-08-09 Heterocyclic compounds for use in the treatment of cancer
GBPCT/GB2019/052240 2019-08-09
GB1917863.1 2019-12-06
GBGB1917863.1A GB201917863D0 (en) 2019-12-06 2019-12-06 Novel compounds
PCT/GB2020/051901 WO2021028670A1 (en) 2019-08-09 2020-08-10 Deuterated compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN114846003A true CN114846003A (zh) 2022-08-02

Family

ID=72039615

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070533.0A Pending CN114846003A (zh) 2019-08-09 2020-08-10 用于治疗癌症的氘代化合物

Country Status (25)

Country Link
US (1) US20220259174A1 (lt)
EP (1) EP4010329B9 (lt)
JP (1) JP2022544211A (lt)
KR (1) KR20220050148A (lt)
CN (1) CN114846003A (lt)
AU (1) AU2020327661A1 (lt)
BR (1) BR112022002496A2 (lt)
CA (1) CA3149119A1 (lt)
DK (1) DK4010329T3 (lt)
ES (1) ES2952281T3 (lt)
FI (1) FI4010329T3 (lt)
HR (1) HRP20231037T1 (lt)
HU (1) HUE063145T2 (lt)
IL (1) IL290415A (lt)
LT (1) LT4010329T (lt)
MX (1) MX2022001690A (lt)
PH (1) PH12022550286A1 (lt)
PL (1) PL4010329T3 (lt)
PT (1) PT4010329T (lt)
RS (1) RS64486B1 (lt)
SI (1) SI4010329T1 (lt)
SM (1) SMT202300266T1 (lt)
TW (1) TW202120486A (lt)
WO (1) WO2021028670A1 (lt)
ZA (1) ZA202201364B (lt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062799A (zh) * 2021-02-07 2023-11-14 阿提奥斯医药有限公司 新的方法
CN118221638A (zh) * 2022-12-19 2024-06-21 艾立康药业股份有限公司 作为DNA聚合酶Theta抑制剂的杂环化合物
WO2024188246A1 (zh) * 2023-03-13 2024-09-19 上海宇道生物技术有限公司 含氮大环类化合物及其制备方法和应用
WO2024260408A1 (zh) * 2023-06-20 2024-12-26 康百达（四川）生物医药科技有限公司 一种吡咯烷衍生物及其在医药上的应用
WO2025113624A1 (zh) * 2023-11-29 2025-06-05 正大天晴药业集团股份有限公司 含吡咯烷酮结构的大环类化合物
WO2026007997A1 (en) * 2024-07-05 2026-01-08 Ningbo Newbay Technology Development Co., Ltd. Macrocyclic compounds and use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028643A1 (en) * 2019-08-09 2021-02-18 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
CN116332905B (zh) * 2021-12-23 2025-07-08 上海翊石医药科技有限公司 (s)-n-苯基-1-(吡啶-2-基)吡咯烷-2-甲酰胺衍生物
WO2023125841A1 (zh) * 2021-12-29 2023-07-06 武汉人福创新药物研发中心有限公司 作为Polθ抑制剂的杂环化合物及其制备方法和用途
TWI856471B (zh) * 2021-12-30 2024-09-21 大陸商上海湃隆生物科技有限公司 一種DNA聚合酶theta抑制劑及其應用
CN118871430A (zh) * 2022-03-10 2024-10-29 西藏海思科制药有限公司 DNA聚合酶 θ 抑制剂及其用途
TW202341987A (zh) * 2022-03-11 2023-11-01 大陸商武漢人福創新藥物研發中心有限公司 一種Polθ抑制劑
WO2024197653A1 (en) * 2023-03-29 2024-10-03 Suzhou Eoc Medical Research Co., Ltd. Heterocyclic compounds and uses thereof
CN116478147B (zh) * 2023-04-25 2025-08-29 深圳开悦生命科技有限公司 抑制rna解旋酶dhx33活性的氘代化合物、合成方法、药物组合物及用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107405A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2013107291A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010626A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and use thereof
CN105829310A (zh) * 2013-12-20 2016-08-03 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
WO2017190637A1 (zh) * 2016-05-06 2017-11-09 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物
CN108137544A (zh) * 2015-12-10 2018-06-08 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
US20190218251A1 (en) * 2018-01-12 2019-07-18 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10130150A (ja) * 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酢酸アミド誘導体からなる医薬
US8629157B2 (en) * 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
WO2021028643A1 (en) * 2019-08-09 2021-02-18 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
CN117062799A (zh) * 2021-02-07 2023-11-14 阿提奥斯医药有限公司 新的方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107405A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2013107291A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010626A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and use thereof
CN105829310A (zh) * 2013-12-20 2016-08-03 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
CN108137544A (zh) * 2015-12-10 2018-06-08 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
WO2017190637A1 (zh) * 2016-05-06 2017-11-09 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物
US20190218251A1 (en) * 2018-01-12 2019-07-18 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAO SUN，等: "Deuterium isotope effects in drug pharmacokinetics II: substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs", 《PLOS ONE》, 14 November 2018 (2018-11-14), pages 0206279 *
李苏，等: "氘代药物及其在抗肿瘤新药研发中的应用前景", 《临床肿瘤学杂志》, 31 December 2020 (2020-12-31), pages 1138 - 1143 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062799A (zh) * 2021-02-07 2023-11-14 阿提奥斯医药有限公司 新的方法
CN118221638A (zh) * 2022-12-19 2024-06-21 艾立康药业股份有限公司 作为DNA聚合酶Theta抑制剂的杂环化合物
CN118221638B (zh) * 2022-12-19 2025-09-19 艾立康药业股份有限公司 作为DNA聚合酶Theta抑制剂的杂环化合物
WO2024188246A1 (zh) * 2023-03-13 2024-09-19 上海宇道生物技术有限公司 含氮大环类化合物及其制备方法和应用
WO2024260408A1 (zh) * 2023-06-20 2024-12-26 康百达（四川）生物医药科技有限公司 一种吡咯烷衍生物及其在医药上的应用
WO2025113624A1 (zh) * 2023-11-29 2025-06-05 正大天晴药业集团股份有限公司 含吡咯烷酮结构的大环类化合物
WO2026007997A1 (en) * 2024-07-05 2026-01-08 Ningbo Newbay Technology Development Co., Ltd. Macrocyclic compounds and use thereof

Also Published As

Publication number Publication date
EP4010329B9 (en) 2023-10-04
ES2952281T3 (es) 2023-10-30
EP4010329A1 (en) 2022-06-15
ZA202201364B (en) 2023-11-29
FI4010329T3 (fi) 2023-08-30
KR20220050148A (ko) 2022-04-22
TW202120486A (zh) 2021-06-01
CA3149119A1 (en) 2021-02-18
HRP20231037T1 (hr) 2023-12-08
HUE063145T2 (hu) 2023-12-28
PT4010329T (pt) 2023-08-18
US20220259174A1 (en) 2022-08-18
JP2022544211A (ja) 2022-10-17
WO2021028670A1 (en) 2021-02-18
MX2022001690A (es) 2022-05-10
IL290415A (en) 2022-04-01
PL4010329T3 (pl) 2023-10-16
EP4010329B1 (en) 2023-06-07
SI4010329T1 (sl) 2023-10-30
AU2020327661A1 (en) 2022-02-24
BR112022002496A2 (pt) 2022-04-26
SMT202300266T1 (it) 2023-09-06
DK4010329T3 (da) 2023-09-04
LT4010329T (lt) 2023-09-11
PH12022550286A1 (en) 2023-04-12
RS64486B1 (sr) 2023-09-29

Similar Documents

Publication Publication Date Title
EP4010329B1 (en) Deuterated compounds for use in the treatment of cancer
US12458640B2 (en) Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors
US12358886B2 (en) Heterocyclic compounds for use in the treatment of cancer
US20240166623A1 (en) Novel process
EP4419526B1 (en) Heterocyclic compounds for use in the treatment of cancer
WO2024187153A1 (en) Compounds targeting mutations in p53 and uses thereof
WO2020030925A1 (en) Heterocyclic substituted ureas, for use against cancer
WO2020030924A1 (en) Thiazoleureas as anticancer agents
HK40076656B (en) Deuterated compounds for use in the treatment of cancer
HK40076656A (en) Deuterated compounds for use in the treatment of cancer
HK40112378B (en) Heterocyclic compounds for use in the treatment of cancer
HK40112378A (en) Heterocyclic compounds for use in the treatment of cancer
WO2024218499A1 (en) Heterocyclic inhibitors of dna polymerase theta for the treatment of cancer
HK40078801A (en) Heterocyclic compounds for use in the treatment of cancer
HK40078801B (en) Heterocyclic compounds for use in the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220802